Wider loss than expected on derivative loss and higher research and development spend. About $38mm in cash. Hey, we even recorded some Onsolis revenues.. ha.
A brief note on the Bunavail litigation can be found towards the bottom. Don't see any nasty surprises in here. I assuming we'll see another stock offering in the future, but probably not until Bema-Bup trial data comes out.